Bio-Rad Laboratories Class A

BIO

Market cap $8.08B

BIO Hedge Fund Activity: Q1 2026 in Review

391 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2026, worth a combined $5.57B — down 5.4% from $5.89B a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new BIO positions and 60 closed out — a net gain of 3 holders — while 142 added to existing stakes and 99 trimmed.

The largest buyer was Capital World Investors, opening a new position worth an estimated $130M. The largest seller was Veritas Asset Management, exiting entirely with an estimated $165M sold.

• 391 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2026, down from 396 in Q4 2025.
• Funds reported $5.57B of Bio-Rad Laboratories Class A stock for Q1 2026, down 5.4% quarter-over-quarter.
• 63 funds opened new Bio-Rad Laboratories Class A positions in Q1 2026 and 60 closed out, a net change of +3 holders.
• The largest Bio-Rad Laboratories Class A buyer in Q1 2026 was Capital World Investors, an estimated $130M added.
• The largest Bio-Rad Laboratories Class A seller in Q1 2026 was Veritas Asset Management, an estimated $165M sold.

Based on aggregated 13F filings for Q1 2026.